medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (5)


Primary hepatic amyloidosis: a mini literature review and five cases report

Ya-Dong W, Cai-Yan Z, Hong-Zhu Y

Idioma: Ingles.
Referencias bibliográficas: 32
Paginas: 721-727
Archivo PDF: 213.04 Kb.


RESUMEN

sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003: 349: 583-96.

  2. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008: 103: 776-87.

  3. Renzulli P, Schoepfer A, Mueller E, Candinas D. Atraumatic splenic rupture in amyloidosis. Amyloid 2009: 16: 47-53.

  4. Gullu BE, Hatemi I, Ozbay G, Tuzuner N, Sonsuz A. A rare case of primary systemic amyloidosis presenting with hepatic failure. Turk J Gastroenterol 2011: 22: 113-4.

  5. Stangou AJ, Rela M, Monaghan M, Mathias CJ, Mufti GJ, O’grady JG, Heaton N. Liver failure in association with hepatic amyloidosis and the role of liver transplantation; the King’s College Hospital exprience. The Liver Meeting® 2010 (AASLD) 2010: 1120.

  6. Black RM (ed.). Amyloidosis and light-chain deposition disease. Clinical problems in nephrology. Boston: Little, Brown; 1996.

  7. Li H, Li XW. A clinical analysis of 33 cases of primary amyloidosis (article in Chinese). Zhanghua Nei Ke Za Zhi 2003: 42: 195-6.

  8. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010: 2010: 287-94.

  9. Sarkar C, Chand Sharma M, Nayak A, Mercy Ralte A, Gupta V, Singh S, Behari M. Primary AL (kappa-light chain) amyloidosis manifesting as peripheral neuropathy in a young male without increase in serum and urine immunoglobulin load: a diagnostic challenge. Clin Neuropathol 2005: 24: 118-25.

  10. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica 2009; 94: 1029-32.

  11. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82: 291-8.

  12. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000: 45: 107-37.

  13. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010;17: 101-4.

  14. McLaurin J, Yang D, Yip CM, Fraser PE. Review: modulating factors in amyloid-beta fibril formation. J Struct Biol 2000; 130: 259-70.

  15. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 2002; 100: 948-53.

  16. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH, Skinner M, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007; 56: 3858-68.

  17. Hung HH, Huang DF, Tzeng CH, Su CH, Su TP, Chen HC, Tsay SH, et al. Systemic amyloidosis manifesting as a rare cause of hepatic failure. J Chin Med Assoc 2010; 73: 161-5.

  18. Bandyopadhyay SK, Bandyopadhyay R, Dutta A. Primary amyloidosis presenting as intrahepatic cholestasis. Indian J Pathol Microbiol 2006; 49: 557-9.

  19. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-80.

  20. Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, Park CH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003; 58: 610-20.

  21. Monzawa S, Tsukamoto T, Omata K, Hosoda K, Araki T, Sugimura K. A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur J Radiol 2002; 41: 237-41.

  22. Shin YM. Hepatic amyloidosis. Korean J Hepatol 2011; 17: 80-3.

  23. Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 2011; 18: 19-24.

  24. Chee CE, Lacy MQ, Dogan A, Zeldenrust SR, Gertz MA. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk 2010; 10: 177-80.

  25. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 180-6.

  26. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 2009; 4: 91-8.

  27. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-8.

  28. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-93.

  29. Ohno S, Yoshimoto M, Honda S, Miyachi S, Ishida T, Itoh F, Endo T, et al. The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002; 169: 4039-45.

  30. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-8.

  31. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011; 86: 251-5.

  32. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-28.




2020     |     www.medigraphic.com